DE60009695D1 - Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion - Google Patents

Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion

Info

Publication number
DE60009695D1
DE60009695D1 DE60009695T DE60009695T DE60009695D1 DE 60009695 D1 DE60009695 D1 DE 60009695D1 DE 60009695 T DE60009695 T DE 60009695T DE 60009695 T DE60009695 T DE 60009695T DE 60009695 D1 DE60009695 D1 DE 60009695D1
Authority
DE
Germany
Prior art keywords
injection
powdery
cabapen
crystalline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009695T
Other languages
English (en)
Other versions
DE60009695T2 (de
Inventor
Hiroyuki Chiba
Masahiko Tsujii
Atsushi Koiwa
Shin Sakurai
Akio Kayano
Hiroyuki Ishizuka
Hiroyuki Saito
Taiju Nakamura
Ikuo Kushida
Yasuyuki Suzuki
Takako Yoshiba
Kazuhide Ashizawa
Masahiro Sakurai
Eiichi Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE60009695D1 publication Critical patent/DE60009695D1/de
Publication of DE60009695T2 publication Critical patent/DE60009695T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
DE60009695T 1999-06-03 2000-06-05 Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion Expired - Lifetime DE60009695T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15681099 1999-06-03
JP15681099 1999-06-03
JP2000153891 2000-05-25
JP2000153891 2000-05-25
PCT/JP2000/003642 WO2000075143A1 (fr) 1999-06-03 2000-06-05 Cristaux de derives de carbapenem et preparations pharmaceutiques pour injection

Publications (2)

Publication Number Publication Date
DE60009695D1 true DE60009695D1 (de) 2004-05-13
DE60009695T2 DE60009695T2 (de) 2004-09-23

Family

ID=26484468

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009695T Expired - Lifetime DE60009695T2 (de) 1999-06-03 2000-06-05 Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion

Country Status (8)

Country Link
US (2) US7084268B1 (de)
EP (1) EP1182204B1 (de)
JP (1) JP4130078B2 (de)
AT (1) ATE263767T1 (de)
AU (1) AU5105100A (de)
CA (1) CA2375601C (de)
DE (1) DE60009695T2 (de)
WO (1) WO2000075143A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642377B1 (en) 1999-07-30 2003-11-04 Eisai Co., Ltd. Process for the preparation of basic antibiotic-inorganic acid addition salts and intermediate oxalates
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
JP2007524619A (ja) * 2003-06-18 2007-08-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶型、その調製方法、これを含有する組成物、およびその使用法
JP2009523132A (ja) * 2006-01-10 2009-06-18 スミスクライン ビーチャム コーポレーション {2−メチル−4−[4−メチル−2−(4−トリフルオロメチルフェニル)チアゾール−5−イルメチルチオ]フェノキシ}−酢酸の多形体形態
JP4954345B1 (ja) * 2011-07-06 2012-06-13 アピ株式会社 医薬品原薬の無菌化精製装置
CN102964348A (zh) * 2012-12-21 2013-03-13 卫宏远 新美罗培南晶型及其制备方法
JP6454323B2 (ja) * 2013-03-15 2019-01-16 パール セラピューティクス,インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
JP2654077B2 (ja) 1988-04-20 1997-09-17 日本レダリー株式会社 結晶形態の1−メチル−カルバペネム化合物
JP3848693B2 (ja) 1994-07-06 2006-11-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規カルバペネム誘導体
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
JPH10152491A (ja) 1996-11-21 1998-06-09 Dai Ichi Seiyaku Co Ltd 結晶性カルバペネム化合物
JP3317649B2 (ja) 1997-01-13 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
DE69829605T2 (de) * 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
WO1998052918A1 (fr) 1997-05-23 1998-11-26 Eisai Co., Ltd. Intermediaires employes a la production de carbapenem et procede de production stereoselective
JP2001512099A (ja) * 1997-07-31 2001-08-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 金属−β−ラクタマーゼ阻害剤としてのメルカプトアシルアミノ酸
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes

Also Published As

Publication number Publication date
JP4130078B2 (ja) 2008-08-06
DE60009695T2 (de) 2004-09-23
EP1182204B1 (de) 2004-04-07
AU5105100A (en) 2000-12-28
CA2375601A1 (en) 2000-12-14
WO2000075143A1 (fr) 2000-12-14
US20060040916A1 (en) 2006-02-23
EP1182204A4 (de) 2002-10-30
ATE263767T1 (de) 2004-04-15
CA2375601C (en) 2008-07-29
EP1182204A1 (de) 2002-02-27
US7084268B1 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
HU9302330D0 (en) 7-(substituted)-9-|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
AU1608692A (en) Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants
HUP0002987A2 (hu) Cefdinir diciklohexil-amin sója és eljárás a só előállítására valamint a vegyület sójából történő felszabadítására
DE69210029D1 (de) Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
NO303734B1 (no) Triazolyltiometyltiocefalosporin-hydroklorid, dets krystallinske hydrat samt farmasaytisk preparat inneholdende dette
HUT66660A (en) Intermediates for producing 9-[(substituted glicyl)-amido]-6-demetyl-6-deoxy-tetracyclines and pharmaceutical compositions containing them
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
ZA935276B (en) 3-(hydroxybenzylidenyl)-indolin-2-ones processes for their preparation and pharmaceutical compositions containing them
ATE263767T1 (de) Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion
AU2101492A (en) Methanoanthracenes having antidopaminergic activity
HU9202642D0 (en) Method for producing piperidine derivatives and pharmaceutical preparatives containing said compounds as active substance
TW252979B (de)
HU903828D0 (en) Process for producing cephem acid additioned salts and pharmaceutical products containing such compounds
DE69026816T2 (de) Bizyklische amino-substituierte verbindungen
GEP20063759B (en) Novel Benzothiazine and Benzothiadiazine Derivatives, Method for Preparing Same and Pharmaceutical Compositions Containing Same
HU9202641D0 (en) Method for producing methano-anthracene derivatives and pharmaceutical preparatives containing said compounds as active substance
HU9202103D0 (en) Method for producing inosite-phosphate analogues and pharmaceutical preparatives containing these compounds
ATE100463T1 (de) Renin-hemmende aminooligohydroxy-derivate.
ZA941056B (en) (Cyclohexyl)alkene compounds processes for preparing them and pharmaceutical compositions containing them
HUT53654A (en) Process for producing cefemcarboxylic acid compounds and pharmaceutical compositions comprising such compounds
IL109227A0 (en) Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them
IT1254562B (it) Forma cristallina dell'endo-3-etil-2,3-diidro-n-(8-metil-8-azabiciclo (3.2.1) ott-3-il)- 2-oxo-1h-benzimidazolo-1-carbossamide cloridrato
AU2134995A (en) 2,4-diphosphonoglutaric acid derivatives, methods of preparing such compounds and drugs containing them
HUT45036A (en) Process for producing new crystalline semi-hydrate of 3-methoxy-4-(4'-amino-benzenesulfonamido)-1,2,5-thiadiazole

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKIO, JP